Decheng Capital LLC
CIK
2010850
Location
MENLO PARK, CA
Portfolio Value
Small
$731,749,065
Diversification
Highly concentrated
Filing Date
Global Rank
#3,070
/ 8,795
▼ 280
· as of Jun 2026
Top Industry
Biotechnology
100.0%
Period ended 3 months ago
Filed Aug 14, 2026 · 54d
11 quarters · since Dec 2023
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
14 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Top Position
61.9%
−3.3 pts
Top 5
90.6%
+0.3 pts
Top 10
98.1%
−0.1 pts
HHI
4,272
Highly concentrated−302
Portfolio Trend
11 quarters · across all stocks
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $731,749,065 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increasedNo qualifying positions this quarter.
Trimmed
Positions the filer reduced
3 positions
New Positions
Positions the filer opened this quarter
1 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| TNGX | Tango Therapeutics, Inc. | 20,000 | $625,200 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
1 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| KRYS | Krystal Biotech, Inc. | 7,300 | $1,885,736 | |
| No positions match the current search. | ||||
14 tracked positions ·
$731,749,065 total
· filing declares
14 positions · $731,749,074
· as of Jun 30, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| CGON |
CG Oncology, Inc.
Healthcare
|
Held | 6,371,669 | $452,707,082 | 61.87% | |
| NUVB |
Nuvation Bio Inc.
Healthcare
|
Held | 25,954,439 | $147,421,213 | 20.15% | |
| AARD |
Aardvark Therapeutics, Inc.
Healthcare
|
Held | 3,917,299 | $22,563,642 | 3.08% | |
| ACRS |
Aclaris Therapeutics, Inc.
Healthcare
|
Held | 4,041,736 | $21,380,783 | 2.92% | |
| UPB |
Upstream Bio, Inc.
Healthcare
|
Held | 2,724,868 | $18,856,086 | 2.58% | |
| RCUS |
Arcus Biosciences, Inc.
Healthcare
|
Reduced | 464,779 | $14,329,136 | 1.96% | |
| EQ |
Equillium, Inc.
Healthcare
|
Held | 4,447,308 | $14,231,385 | 1.94% | |
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
Reduced | 52,667 | $9,863,475 | 1.35% | |
| LYEL |
Lyell Immunopharma, Inc.
Healthcare
|
Held | 692,050 | $9,723,302 | 1.33% | |
| BYSI |
BeyondSpring Inc.
Healthcare
|
Held | 3,800,702 | $6,651,228 | 0.91% | |
| ZNTL |
Zentalis Pharmaceuticals, Inc.
Healthcare
|
Held | 1,323,327 | $6,418,135 | 0.88% | |
| NAMS |
NewAmsterdam Pharma Co N.V.
Healthcare
|
Reduced | 176,887 | $5,994,700 | 0.82% | |
| PYXS |
Pyxis Oncology, Inc.
Healthcare
|
Held | 326,810 | $983,698 | 0.13% | |
| TNGX |
Tango Therapeutics, Inc.
Healthcare
|
NEW | 20,000 | $625,200 | 0.09% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.